Summary of Korean Asthma Guideline
- Authors
- Rhee, Chin Kook; Moon, Ji-Yong; Joo, Hyonsoo; Jung, Ji Ye; Lee, Jung-Kyu; Min, Kyung Hoon; Koo, Hyeon-Kyoung; Lim, Seong Yong; Yoon, Hyoung Kyu; Lee, Sang Yeub
- Issue Date
- Jul-2023
- Publisher
- TAEHAN KYORHAEK HYOPHOE-KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASES
- Keywords
- Asthma; Guideline; Korea
- Citation
- TUBERCULOSIS AND RESPIRATORY DISEASES, v.86, no.3, pp.158 - 165
- Indexed
- SCOPUS
KCI
- Journal Title
- TUBERCULOSIS AND RESPIRATORY DISEASES
- Volume
- 86
- Number
- 3
- Start Page
- 158
- End Page
- 165
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/188392
- DOI
- 10.4046/trd.2023.0052
- ISSN
- 1738-3536
- Abstract
- Asthma is a chronic inflammatory airway disease that is characterized by variable airflow obstruction. The Korean Asthma Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases has recently updated the Korean Asthma Guideline. This review summarizes the updated Korean Asthma Guideline. Asthma prevalence is increasing worldwide, and in Korea. Variable airflow obstruction can be confirmed by bronchodilator response or other tests, and should be established prior to the controller medication. A low-dose inhaled corticosteroid-formoterol is used to alleviate symptoms in all treatment step, and it can be used as a controller as well as reliever in steps 3-5. This approach is preferred, because it reduces the risk of severe exacerbations, compared to the use of short-acting β2-agonist as reliever. In severe asthma, phenotype/endotype based on the underlying inflammation should be evaluated. For type 2 severe asthma, the biologics should be considered.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/188392)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.